Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,213 across all filing types
Latest filing 2024-05-30 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a short announcement (1593 characters) from the board of directors about a product development update, specifically the approval of a drug for registration. It is labeled as a "Voluntary Announcement" and is intended to inform shareholders and investors about business developments. There is no financial data, no mention of financial results, no regulatory filings or voting results, and no detailed report attached or referenced. The content is clearly an update on business/product development rather than a formal financial or regulatory report. Given the short length and nature of the content, it fits best under the category of a general regulatory or business update announcement. The closest fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2024-05-30 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from the board of directors regarding updates on product development, specifically approvals from the National Medical Products Administration of China for certain drug products. It is not a financial report, earnings release, or regulatory filing related to financial performance. The document is relatively short (2260 characters) and serves to inform shareholders and investors about business developments rather than detailed financial data or governance changes. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing or certification. The content is an update announcement on product development, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-05-30 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors regarding an update on product development, specifically the approval of a new specification and passing of a regulatory evaluation for a pharmaceutical product. It is not a financial report, earnings release, or regulatory filing related to financial performance. The document is short (1681 characters) and serves to inform shareholders and investors about business developments rather than financial results or governance changes. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing or certification. The best fitting category is a general Regulatory Filing (RNS) as it is a regulatory announcement about product development and business updates that do not fall into more specific categories.
2024-05-28 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from the board of directors regarding an update on product development, specifically the approval for drug production and registration. It is not a financial report, earnings release, or regulatory filing related to financial performance or governance changes. The document is short (1714 characters) and serves to inform shareholders and investors about business developments rather than financial results or corporate governance matters. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is an announcement of business progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-05-27 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Capital/Financing Update Classification · 85% confidence The document is a voluntary announcement by the board of directors regarding the approval of a product (Formoterol Fumarate) by a regulatory body (National Medical Products Administration of China). It is an update on product development and does not contain financial data, regulatory certifications, or meeting materials. The document is short (1593 characters) and serves to inform shareholders and investors about business progress rather than financial results or governance changes. It is not an annual report, earnings release, management report, or any other detailed financial or governance filing. It is also not a regulatory filing or report publication announcement since it provides substantive business update information. Therefore, the best fitting category is a Capital/Financing Update (CAP) as it relates to business development and product approval impacting company operations and potential capital value.
2024-05-22 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors regarding the approval of a drug product development from a regulatory authority (NMPA). It is an update on business development rather than a financial report or regulatory filing. The document is short (1913 characters) and does not contain financial data, earnings, or management discussion. It is not an announcement of voting results, nor a report on board changes. It is a general business update announcement. Given the content and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2024-05-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.